Item

A 15% Trichloroacetic Acid + 3% Glycolic Acid Chemical Peel Series Improves Appearance of Hand Lentigines: An Evaluator-Blinded, Split-Hand Prospective Trial

Alajmi, Ali
Niaz, Ghassan
Chen, Christine
Lee, Kachiu
Citations
Altmetric:
Genre
Journal article
Date
2024-03-08
Advisor
Committee member
Group
Department
Dermatology
Subject
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1097/dss.0000000000004114
Abstract
BACKGROUND: Improving the appearance of lentigines on the hands is a key component to hand rejuvenation. Soft tissue fillers revolumize hands, but do not address pigmentary changes. OBJECTIVE: This study investigated the effiacy of a 15% trichloroacetic acid (TCA) + 3% glycolic acid (GA) combination peel in improvement of appearance of hand lentigines. METHODS A prospective evaluator-blinded, split-hand study was performed using a 15% TCA + 3% GA peel to treat patients with hand lentigines. Subjects received a total of 3 treatments at 4-week intervals on 1 hand, with the other hand serving as an untreated control. Final photographs were taken 12 weeks after the last treatment. Two blinded board-certified dermatologists graded improvement in hand lentigines using a 5-point scale. RESULTS Eighteen of 20 patients completed the study (90%). The mean age was 64.4 years (SE 1.6, range 51–71). The mean pain scores were 3.8 (SE 0.4) on a 10-point scale (1 = no pain, 10 = extremely painful). Blinded evaluators correctly identified the after-treatment photographs in 16 patients (88%). Physician and patient-graded mean improvement of lentigines was significant for treated versus control hands (p < .01). No adverse events were noted. CONCLUSION A series of three 15% TCA + 3% GA peels are effective and safe in the treatment of hand lentigines.
Description
Citation
Alajmi, Ali MD; Niaz, Ghassan MD, Chen, Christine BA; Lee, Kachiu MD, MPH. A 15% Trichloroacetic Acid + 3% Glycolic Acid Chemical Peel Series Improves Appearance of Hand Lentigines: An Evaluator-Blinded, Split-Hand Prospective Trial. Dermatologic Surgery 50(5):p 467-470, May 2024. DOI: 10.1097/DSS.0000000000004114
Citation to related work
Ovid Technologies (Wolters Kluwer Health)
Has part
Dermatologic Surgery, Vol. 50, Iss. 5
ADA compliance
Embedded videos
License
Attribution-NonCommercial-NoDerivs CC BY-NC-ND